Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Dermatology Reports
Published in: Current Dermatology Reports 3/2023

30-06-2023 | Pruritus | REVIEW

Pruritus: An Approach to Diagnosis and Management for the Inpatient Dermatologist

Authors: Georgia Biazus Soares, Gil Yosipovitch

Published in: Current Dermatology Reports | Issue 3/2023

Login to get access

Abstract

Purpose of Review

This review provides a framework to categorize causes of pruritus that may present in the inpatient dermatology setting and highlights therapeutic options for these pruritic conditions.

Recent Findings

Various pruritogens have been implicated in dermatologic and systemic diseases, and itch characteristics may differ depending on etiology. Biologics have emerged as effective therapies for pruritus associated with dermatologic conditions. Novel treatment options for pruritus associated with systemic diseases include difelikefalin for CKD pruritus, butorphanol and ileal bile acid transporters for cholestatic pruritus, and biologics for several systemic etiologies.

Summary

Pruritus has multiple etiologies, is often difficult to diagnose and treat, and can have a significant impact on quality of life. Various pruritic conditions may present in the inpatient setting, and dermatologists should be able to effectively diagnose and manage these patients.
Literature
1.
Kini SP, DeLong LK, Veledar E, McKenzie-Brown AM, Schaufele M, Chen SC. The impact of pruritus on quality of life: the skin equivalent of pain. Arch Dermatol. 2011;147(10):1153–6.PubMedCrossRef
2.
Madigan LM, Fox LP. Where are we now with inpatient consultative dermatology?: Assessing the value and evolution of this subspecialty over the past decade. J Am Acad Dermatol. 2019;80(6):1804–8.PubMedCrossRef
3.
Joseph J, Truong K, Smith A, Fernandez-Penas P. Dermatology inpatient consultations in a tertiary hospital–a retrospective analysis. Int J Dermatol. 2022;61(1):48–53.PubMedCrossRef
4.
Roh YS, Choi J, Sutaria N, Kwatra SG. Itch: Epidemiology, clinical presentation, and diagnostic workup. J Am Acad Dermatol. 2022;86(1):1–14.PubMedCrossRef
5.
Lipman ZM, Ingrasci G, Yosipovitch G. Approach to the patient with chronic pruritus. Med Clin. 2021;105(4):699–721.
6.
Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502–7.PubMedCrossRef
7.
Lay C-J, Wang C-L, Chuang H-Y, Chen Y-L, Chen H-L, Tsai S-J, et al. Risk factors for delayed diagnosis of scabies in hospitalized patients from long-term care facilities. J  Clin Med Res. 2011:72–7.
8.
• Tso S, Satchwell F, Moiz H, Hari T, Dhariwal S, Barlow R, et al. Erythroderma (exfoliative dermatitis). Part 1: underlying causes, clinical presentation and pathogenesis. Clin Exp Dermatol. 2021;46(6):1001–10. Provides a comprehensive review of causes and pathophysiology of erythroderma.
9.
Sarkar R, Sharma RC, Koranne RV, Sardana K. Erythroderma in children: a clinico-etiological study. J Dermatol. 1999;26(8):507–11.PubMedCrossRef
10.
Askin O, Altunkalem RN, Uzuncakmak TK, Toplu FŞ, Engin B. Erythroderma: a clinicopathological study of 47 cases from 2018 to 2020. Dermatol Ther. 2020;33(6): e14342.PubMedCrossRef
11.
12.
•• Paller AS, Silverberg JI, Cork MJ, Guttman-Yassky E, Lockshin B, Irvine AD, et al. Efficacy and safety of dupilumab in patients with erythrodermic atopic dermatitis: a post hoc analysis of 6 randomized clinical trials. JAMA Dermatol. 2023. Post-hoc anaylsis showing that dupilumab effectively reduces percentage of body surface area affected, EASI score, and peak pruritus NRS score in patients with erythrodermic AD.
13.
Cuellar-Barboza A, Ocampo-Candiani J, Herz-Ruelas M. A practical approach to the diagnosis and treatment of adult erythroderma. Actas Dermo-Sifiliográficas (English Edition). 2018;109(9):777–90.CrossRef
14.
Labib A, Does AV, Korbutov J, Yosipovitch G. Silicone barrier cream in treatment of atopic dermatitis: a literature review. Dermatol Ther. 2022:e15884.
15.
• Chung BY, Kim HB, Jung MJ, Kang SY, Kwak I-S, Park CW, et al. Post-burn pruritus. Int J Mol Sci. 2020;21(11):3880. Provides a comprehensive review of post-burn pruritus.
16.
Fowler E, Yosipovitch G. Post-burn pruritus and its management—current and new avenues for treatment. Curr Trauma Rep. 2019;5(2):90–8.CrossRef
17.
Goutos I, Clarke M, Upson C, Richardson PM, Ghosh SJ. Review of therapeutic agents for burns pruritus and protocols for management in adult and paediatric patients using the GRADE classification. Ind J Plastic Surg. 2010;43(S 01):S51-S62.
18.
Ahuja RB, Gupta GK. A four arm, double blind, randomized and placebo controlled study of pregabalin in the management of post-burn pruritus. Burns. 2013;39(1):24–9.PubMedCrossRef
19.
Storan ER, McEvoy MT, Wetter DA, el-Azhary RA, Hand JL, Davis DM, et al. Pediatric hospital dermatology: experience with inpatient and consult services at the Mayo Clinic. Pediatr Dermatol. 2013;30(4):433–7.
20.
Cathcart S, Theos A. Inpatient management of atopic dermatitis. Dermatol Ther. 2011;24(2):249–55.PubMedCrossRef
21.
• Narla S, Silverberg JI. Management of atopic dermatitis in the inpatient setting. Curr Dermatol Rep. 2021;10(3):77–88. Provides an updated review for the management of AD in the inpatient setting and highlights the benefit of a multidisciplinary approach.
22.
Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2016;51(3):263–92.PubMedCrossRef
23.
Prodanovich S, Kirsner RS, Taylor JR. Treatment of patients hospitalized for psoriasis. Dermatol Clin. 2000;18(3):425–35.PubMedCrossRef
24.
25.
Wang Q, Jin L, Hu K, Tan M, Lu Y, Zhao Y, et al. The length of stay and inpatient burden in inpatients with different psoriasis subtypes. Int J Med Sci. 2022;19(10):1519–24.PubMedPubMedCentralCrossRef
26.
Miyachi H, Konishi T, Kumazawa R, Matsui H, Shimizu S, Fushimi K, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86(6):1266–74.PubMedCrossRef
27.
Hadeler E, Mosca M, Hong J, Brownstone N, Liao W, Bhutani T, et al. Inpatient management of psoriasis: a current perspective and update for clinicians. Curr Dermatol Rep. 2021:1–17.
28.
Kahremany S, Hofmann L, Harari M, Gruzman A, Cohen G. Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives. Pharmacol Rep. 2021;73(2):443–53.PubMedCrossRef
29.
Vensel E, Hilley T, Trent J, Taylor JR, Kirsner RS, Kerdel FA, et al. Sustained improvement of the quality of life of patients with psoriasis after hospitalization. J Am Acad Dermatol. 2000;43(5):858–60.PubMedCrossRef
30.
Giannotti B, Carli P, Veller-Fornasa C, Cancian G, Fadel A, Amerio P, et al. Management of erythrodermic psoriasis with low-dose cyclosporin. Dermatology. 1993;187(SUPPL. 1):30–7.
31.
Yosipovitch G, Soung J, Weiss J, Muscianisi E, Meng X, Gilloteau I, et al. Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials. Acta Derm Venereol. 2019;99(9):820–1.PubMedCrossRef
32.
Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Nikaï E, et al. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials. J Am Acad Dermatol. 2016;75(6):1156–61.PubMedCrossRef
33.
•• Maçães CO, Lé AM, Torres T. Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors. J Dermatol Treat. 2022;33(7):2911–8. Highlights clinical trials that evaluate the efficacy of IL-36 inhibitors in treating psoriasis flares.
34.
Baigrie D, Nookala V. Bullous Pemphigoid. StatPearls [Internet]: StatPearls Publishing; 2021.
35.
Hashimoto T, Kursewicz CD, Fayne RA, Nanda S, Shah SM, Nattkemper L, et al. Pathophysiologic mechanisms of itch in bullous pemphigoid. J Am Acad Dermatol. 2020;83(1):53–62.PubMedCrossRef
36.
Ren Z, Hsu D, Brieva J, Silverberg N, Langan S, Silverberg J. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the USA. Br J Dermatol. 2017;176(1):87–99.PubMedCrossRef
37.
Bernard P, Antonicelli F. Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am J Clin Dermatol. 2017;18(4):513–28.PubMedCrossRef
38.
•• Abdat R, Waldman RA, de Bedout V, Czernik A, Mcleod M, King B, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83(1):46–52. In this case series, 11 out of 13 bullous pemphigoid patients reported resolution of their itch while using dupilumab.
39.
London VA, Kim GH, Fairley JA, Woodley DT. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol. 2012;148(11):1241–3.PubMedCrossRef
40.
Kenneth KY, Crew AB, Messingham KA, Fairley JA, Woodley DT. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71(3):468–74.CrossRef
41.
Lipozenčić J, Ljubojevic S, Bukvić-Mokos Z. Pemphigoid gestationis. Clin Dermatol. 2012;30(1):51–5.PubMedCrossRef
42.
Palmsten K, Bandoli G, Watkins J, Vazquez-Benitez G, Gilmer TP, Chambers CD. Oral corticosteroids and risk of preterm birth in the California Medicaid program. The J Allergy Clin Immunol: In Practice. 2021;9(1):375–84. e5.
43.
Palmsten K, Bandoli G, Vazquez-Benitez G, Xi M, Johnson DL, Xu R, et al. Oral corticosteroid use during pregnancy and risk of preterm birth. Rheumatology. 2020;59(6):1262–71.PubMedCrossRef
44.
Riquelme-Mc Loughlin C, Mascaró J Jr. Treatment of pemphigoid gestationis with dupilumab. Clin Exp Dermatol. 2021;46(8):1578–9.PubMedCrossRef
45.
Shakuntulla F, Chiarella SE. Safety of biologics for atopic diseases during pregnancy. J Allergy Clin Immunol: In Practice. 2022;10(12):3149–55.
46.
47.
• Ottevanger R, van Beugen S, Evers AW, Willemze R, Vermeer MH, Quint KD. Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator. JAAD Int. 2022;9:57–64. This cross-sectional cohort study showed that itch correlates significantly with a more impaired quality of life in patients with CTCL.
48.
Nattkemper LA, Martinez-Escala M-E, Gelman AB, Singer EM, Rook AH, Guitart J, et al. Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin. Acta Derm-Venereol. 2016;96(7).
49.
Cedeno-Laurent F, Singer EM, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol. 2015;158(1):1–7.PubMedPubMedCentralCrossRef
50.
51.
Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2015;73(5):843–8.PubMedCrossRef
52.
Nusbaum KB, Walker TD, Himed S, Trinidad JC, Spaccarelli N, Chung C, et al. Patient care outcomes in hospitalized patients with acute generalized exanthematous pustulosis: a cross-sectional database study. Am J Clin Dermatol. 2022:1–6.
53.
Hadavand MA, Kaffenberger B, Cartron AM, Trinidad JC. Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis. J Am Acad Dermatol. 2020.
54.
Munshi M, Junge A, Gadaldi K, Yawalkar N, Heidemeyer K. Ixekizumab for treatment of refractory acute generalized exanthematous pustulosis caused by hydroxychloroquine. JAAD case reports. 2020;6(7):634–6.PubMedPubMedCentralCrossRef
55.
• Cheng A-Y, Wong L-S. Uremic pruritus: from diagnosis to treatment. Diagnostics. 2022;12(5):1108. Comprehensive review that describes how to diagnose uremic pruritus and provides an overview of novel treatment options.
56.
Hashimoto T, Yosipovitch G. Itching as a systemic disease. J Allergy Clin Immunol. 2019;144(2):375–80.PubMedCrossRef
57.
Oweis AO, Firas A-Q, Bodoor K, Heis L, Alfaqih MA, Almomani R, et al. Elevated interleukin 31 serum levels in hemodialysis patients are associated with uremic pruritus. Cytokine. 2021;138: 155369.PubMedCrossRef
58.
Fallahzadeh MK, Roozbeh J, Geramizadeh B, Namazi MR. Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications. Nephrol Dial Transplant. 2011;26(10):3338–44.PubMedCrossRef
59.
Lipman ZM, Paramasivam V, Yosipovitch G, Germain MJ. Clinical management of chronic kidney disease-associated pruritus: current treatment options and future approaches. Clin Kidney J. 2021;14(Supplement_3):i16-i22.
60.
•• Fishbane S, Jamal A, Munera C, Wen W, Menzaghi F. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med. 2020;382(3):222–32. Phase III trial showing that difelikefalin improves pruritus in patients undergoing hemodialysis, with 51.9% of patients reporting a decrease of at least 3 points in worst itch intensity NRS compared to 30.9% in placebo group.
61.
Ko MJ, Yang JY, Wu HY, Hu FC, Chen SI, Tsai PJ, et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. Br J Dermatol. 2011;165(3):633–9.PubMedCrossRef
62.
Sherjeena PB, Binitha MP, Rajan U, Sreelatha M, Sarita S, Nirmal C, et al. A controlled trial of narrowband ultraviolet B phototherapy for the treatment of uremic pruritus. Indian J Dermatol Venereol Leprol. 2017;83:247.PubMedCrossRef
63.
Beuers U, Wolters F, Oude Elferink RP. Mechanisms of pruritus in cholestasis: understanding and treating the itch. Nat Rev Gastroenterol Hepatol. 2022:1–11.
64.
Smith DD, Rood KM. Intrahepatic cholestasis of pregnancy. Clin Obstet Gynecol. 2020;63(1):134–51.PubMedCrossRef
65.
Feldman AG, Sokol RJ, editors. Recent developments in diagnostics and treatment of neonatal cholestasis. Semin Pediatr Surg. 2020: Elsevier.
66.
• Golpanian RS, Yosipovitch G, Levy C. Use of butorphanol as treatment for cholestatic itch. Dig Dis Sci. 2021;66(5):1693–9. Case series in which 62.5% of patients showed improvement in cholestatic itch severity with butorphanol treatment.
67.
•• Vander Does A, Levy C, Yosipovitch G. Cholestatic itch: our current understanding of pathophysiology and treatments. Am J Clin Dermatol. 2022:1–13. Updated literature review on treatments for cholestatic pruritus.
68.
Ahmed W, Jeyaraj R, Reffitt D, Devlin J, Suddle A, Hunt J, et al. Nasobiliary drainage: an effective treatment for pruritus in cholestatic liver disease. Frontline Gastroenterol. 2022.
69.
Ferraz Gonçalves JA, Rosendo E, Sousa L, Lopes AR, Leão I, Queirós R, et al. Complications of biliary drainage in patients with malignant biliary obstruction. J Gastrointest Cancer. 2021;52(3):1067–72.PubMedCrossRef
70.
Chatterjee N, Chattopadhyay C, Sengupta N, Das C, Sarma N, Pal SK. An observational study of cutaneous manifestations in diabetes mellitus in a tertiary care Hospital of Eastern India. Ind J Endocrinol Metab. 2014;18(2):217.CrossRef
71.
Niepomniszcze H, Huaier AR. Skin disorders and thyroid diseases. J Endocrinol Invest. 2001;24(8):628–38.PubMedCrossRef
72.
Tan C, Loh K. Generalised pruritus as a presentation of Grave’s disease. Malays Fam Phys. 2013;8(1):20.
73.
Brandt F, Green A, Hegedüs L, Brix TH. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol. 2011;165(4):491–7.PubMedCrossRef
74.
Stefaniak AA, Krajewski PK, Bednarska-Chabowska D, Bolanowski M, Mazur G, Szepietowski JC. Itch in adult population with type 2 diabetes mellitus: clinical profile, pathogenesis and disease-related burden in a cross-sectional study. Biology. 2021;10(12):1332.PubMedPubMedCentralCrossRef
75.
76.
Milazzo F, Piconi S, Trabattoni D, Magni C, Coen M, Capetti A, et al. Intractable pruritus in HIV infection: immunologic characterization. Allergy. 1999;54(3):266–72.PubMedCrossRef
77.
Kaushik SB, Cerci FB, Miracle J, Pokharel A, Chen SC, Chan YH, et al. Chronic pruritus in HIV-positive patients in the southeastern United States: its prevalence and effect on quality of life. J Am Acad Dermatol. 2014;70(4):659–64.PubMedCrossRef
78.
Navarini AA, Stoeckle M, Navarini S, Mossdorf E, Jullu BS, Mchomvu R, et al. Antihistamines are superior to topical steroids in managing human immunodeficiency virus (HIV)-associated papular pruritic eruption. Int J Dermatol. 2010;49(1):83–6.PubMedCrossRef
79.
Lim HW, Vallurupalli S, Meola T, Soter NA. UVB phototherapy is an effective treatment for pruritus in patients infected with HIV. J Am Acad Dermatol. 1997;37(3):414–7.PubMedCrossRef
80.
Maurer T, Poncelet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus–infected subjects: efficacy and risk of neuropathy. Arch Dermatol. 2004;140(7):845–9.PubMedCrossRef
81.
Blanes M, Belinchon I, Portilla J, Betlloch I, Reus S, Sánchez-Payá J. Pruritus in HIV-infected patients in the era of combination antiretroviral therapy: a study of its prevalence and causes. Int J STD AIDS. 2012;23(4):255–7.PubMedCrossRef
82.
Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest. 2010;40(9):828–34.PubMedCrossRef
83.
84.
Gobbi PG, Attardo-Parrinello G, Lattanzio G, Rizzo SC, Ascari E. Severe pruritus should be a B-symptom in Hodgkin’s disease. Cancer. 1983;51(10):1934–6.PubMedCrossRef
85.
Núñez-Hipólito L, Moya-Martínez C, Requena L. Generalized pruriginous eruption on a patient with leukemia. JAMA Dermatol. 2020;156(12):1369–70.PubMedCrossRef
86.
• Fourzali K, Yosipovitch G, Maderal A. An approach to hypereosinophilic syndrome presenting with cutaneous features. Dermatitis®. 2022;33(6):387–95. Provides a dermatology-centered approach for diagnosing and managing hypereosinophilic syndrome.
87.
Wieser JK, Kuehn GJ, Prezzano JC, Cusick EH, Stiegler JD, Scott GA, et al. Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment. JAAD Case Reports. 2020;6(4):292–5.PubMedPubMedCentralCrossRef
88.
Reich A, Ständer S, Szepietowski JC. Drug-induced pruritus: a review. Acta Derm Venereol. 2009;89(3):236–44.PubMedCrossRef
89.
Lipman ZM, Yosipovitch G. Substance use disorders and chronic itch. J Am Acad Dermatol. 2021;84(1):148–55.PubMedCrossRef
90.
Steckelings UM, Artuc M, Wollschläger T, Wiehstutz S, Henz B. Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta dermato-venereologica. 2001;81(5).
91.
Fischer A, Rosen AC, Ensslin CJ, Wu S, Lacouture ME. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. Dermatol Ther. 2013;26(2):135–48.PubMedCrossRef
92.
Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28(4):254–63.PubMedCrossRef
93.
Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol. 2019;37(30):2746.PubMedPubMedCentralCrossRef
94.
Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012;13(10):1020–4.PubMedCrossRef
95.
Stumpf A, Ständer S. Neuropathic itch: diagnosis and management. Dermatol Ther. 2013;26(2):104–9.PubMedCrossRef
96.
97.
• Ingrasci G, Tornes L, Brown A, Delgado S, Hernandez J, Yap QV, et al. Chronic pruritus in multiple sclerosis and clinical correlates. J Eur Acad Dermatol Venereol. 2022. Cross-sectional study that assesses itch characteristics in multiple sclerosis patients.
98.
Cohen OS, Chapman J, Lee H, Nitsan Z, Appel S, Hoffman C, et al. Pruritus in familial Creutzfeldt-Jakob disease: a common symptom associated with central nervous system pathology. J Neurol. 2011;258(1):89–95.PubMedCrossRef
99.
Shabtai H, Nisipeanu P, Chapman J, Korczyn A. Pruritus in Creutzfeldt-Jakob disease. Neurology. 1996;46(4):940–1.PubMedCrossRef
100.
Mazeh D, Melamed Y, Cholostoy A, Aharonovitzch V, Weizman A, Yosipovitch G. Itching in the psychiatric ward. Acta dermato-venereologica. 2008;88(2).
101.
Kretzmer GE, Gelkopf M, Kretzmer G, Melamed Y. Idiopathic pruritus in psychiatric inpatients: an explorative study. Gen Hosp Psychiatry. 2008;30(4):344–8.PubMedCrossRef
102.
Buteau A, Reichenberg J. Psychogenic pruritus and its management. Dermatol Clin. 2018;36(3):309–14.PubMedCrossRef
103.
Misery L, Dutray S, Chastaing M, Schollhammer M, Consoli SG, Consoli SM. Psychogenic itch. Transl Psychiatry. 2018;8(1):1–8.CrossRef
104.
Meehan WJ, Badreshia S, Mackley CL. Successful treatment of delusions of parasitosis with olanzapine. Arch Dermatol. 2006;142(3):352–5.PubMedCrossRef
105.
Vouk-Kamenski J, Vukojevic J, Celic I. Successful treatment of delusional infestation with olanzapine depot. Alpha psychiatry (Online). 2021;22(6):324–7.
Metadata
Title
Pruritus: An Approach to Diagnosis and Management for the Inpatient Dermatologist
Authors
Georgia Biazus Soares
Gil Yosipovitch
Publication date
30-06-2023
Publisher
Springer US
Keyword
Pruritus
Published in
Current Dermatology Reports / Issue 3/2023
Electronic ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-023-00392-x

Other articles of this Issue 3/2023

Current Dermatology Reports 3/2023 Go to the issue

REVIEW

Blood Flow’s Effect on Percutaneous Absorption in Animal Models: A Systematic Review

Correction

Correction to: Occupational Contact Dermatitis: An Individualized Approach to the Worker with Dermatitis

REVIEW

An Integrated Teledermatology Model: Attacking Access to Skin Care in a Rural State

REVIEW

Clinical Features and Management of Dermatologic Immune-Related Adverse Events for the Inpatient Dermatologist

REVIEW

Recognition and Management of Necrotizing Neutrophilic Dermatoses

REVIEW

Pseudomonas—Spectrum of Disease Presentations for the Inpatient Dermatologist